Our first product is a multivalent SARS coronavirus vaccine candidate composed of an antigen designed from regions of the spike protein of the SARS coronavirus close to the host receptor. Multivalent antigens are displayed on a multiplex self-assembling nanoparticle. This multiplex nanoparticle enhances immune response and will reduce the number of challenges necessary for immunization.

Parallel Tracks

Phylex BioSciences follows parallel tracks for preclinical-grade manufacturing and cGMP manufacturing of our candidate vaccines. This will allow the company to move directly into cGMP production after our preclinical immunogenicity and protection studies are completed.

Phylex BioSciences follows parallel tracks for the formulation and delivery of our candidate vaccines, including mRNA delivery . The immunogenicity results of our multiplex nanoparticle with various adjuvants and of mRNA encoding our multiplex nanoparticle will be obtained at the same time.

Phylex BioSciences is pursuing a mRNA formulation with the objective of eliminating cold chain logistics for our candidate mRNA vaccine.

Phylex BioSciences is pursuing an accelerated development of stable cell lines with the latest technology that allows us to obtain cGMP manufacturing-ready cells within months of results of immunogenicity studies.